PIK3CA and prostate carcinoma: Notably, PIK3CA mutation and PTEN loss coexist in prostate cancer patients and synergistically can cooperate in vivo to accelerate carcinogenesis and cancer progression via PAM pathway hyperactivation [70, 71].